Optimizing antifungal strategies to improve patient survival

Abstract

Report from the 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2016), 9–12 April Amsterdam, The Netherlands Invasive fungal infections are a major threat to the lives of the increasing number of immunocompromized patients, but neutropenic hemato-oncology patients are at especially high risk. Since effective antifungal treatment and prophylaxis are critical to improve survival in these patients, the emergence of antifungal drug resistance has become an increasing cause of concern. Mortality from invasive fungal infection also remains high even when patients receive appropriate and timely antifungal therapy. These important topics were among those discussed by the over 11,600 clinical microbiologists and infectious disease physicians from more than 120 countries attending the 26th European Congress of Clinical Microbiology and Infectious Diseases.